



Revision date 13-Jun-2025 Version 4 Page 1/12

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Hydromorphone Hydrochloride Injection, USP CII (Hospira Inc.)

Product Code(s) PZ03091

Trade Name: Hydromorphone Hydrochloride Injection, USP

Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as Analgesic

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company Pfizer Ireland Pharmaceuticals

275 North Field Drive OSG Building

Lake Forest, Illinois 60045 Ringaskiddy, Co. Cork.

1-800-879-3477 Ireland

+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification.

Reproductive toxicity Category 2 - (H361d)

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4



Signal word Warning

Hazard statements H361d - Suspected of damaging the unborn child

Precautionary Statements - EU (§28, P201 - Obtain special instructions before use

1272/2008)

P202 - Do not handle until all safety precautions have been read and understood P280 - Wear protective gloves/protective clothing/eye protection/face protection

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/container in accordance with local, regional, national, and

Page 2/12

international regulations as applicable

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

PBT & vPvB The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information This product does not contain any known or suspected endocrine disruptors.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Hydromorphone Hydrochloride (CAS #: 71-68-1)	0.1-0.4		200-762-6	Acute Tox 3 (H301)(H361d)	Not classified	No data available	No data available
Citric acid (CAS #: 77-92-9)	< 1		201-069-1 (607-750-00-3)	Eye Irrit. 2A (H319)SE 3 (H335)	Not classified	No data available	No data available

Page 3/12

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Sodium Citrate (CAS #: 6132-04-3)	*		612-118-5	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg		Inhalation LC50 - 4	Inhalation LC50 - 4	Inhalation LC50 - 4
		mg/kg	hour - dust/mist - mg/L	hour - vapor - mg/L	hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Hydromorphone Hydrochloride 71-68-1	199	No data available	No data available	No data available	No data available
Citric acid 77-92-9	5400	>2000	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

* Proprietary

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation Remove to fresh air. Seek immediate medical attention/advice.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

Skin contact Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

effects Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

chemical

Not applicable.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available. **Sensitivity to static discharge** No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Page 4/12

Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean

spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing.

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors,

Page 5/12

HEPA filtration systems or other equivalent controls.

General hygiene considerations Ha

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Hydromorphone Hydrochloride

Pfizer OEL TWA-8 Hr: 7 TWA; 40 STEL µg/m³, Sensitizer

Citric acid

Czech Republic 4 mg/m³

Germany DFG TWA-MAK: 2 mg/m³; I(2);inhalable fraction

Peak: 4 mg/m³; respirable fraction

Germany TRGS TWA-AGW; 2 mg/m³ (exposure factor 2); inhalable fraction

Russia MAC: 1 mg/m³

Switzerland TWA-MAK: 2 mg/m³; inhalable dust

STEL-KZGW: 4 mg/m³; inhalable dust

8.2. Exposure controls

Engineering controls Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in

the workplace and specific operational processes.

Eye/face protection Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with

drug product is possible and for bulk processing operations. (Protective gloves must meet

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Page 6/12

Skin and body protection Impervious disposable protective clothing is recommended if skin contact with drug product

is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter).

(Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10

or international equivalent.).

No information available. Thermal hazards

Environmental exposure controls No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance Solution **Physical state** Liquid Color Colorless

No information available. Odor **Odor threshold** No information available

Property Values

Melting point / freezing point No data available Boiling point or initial boiling point and boiling range No data available Flammability (solid, gas) No data available

Lower and upper explosion limit/flammability limit

Lower explosion limit No data available No data available **Upper explosion limit** Flash point No data available

Autoignition temperature No data available

Decomposition temperature

No data available SADT (°C)

pН 3.5-5.5

pH (as aqueous solution) No data available Kinematic viscosity No data available Dynamic viscosity No data available Solubility No data available Vapor pressure No data available Density and/or relative density No data available No data available **Bulk density**

Liquid Density No data available Vapor density No data available

Particle characteristics

Particle Size No information available **Particle Size Distribution** No information available

9.2. Other information

Molecular formula Mixture Mixture Molecular weight

Page 7/12

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available. **Sensitivity to static discharge** No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materialsAs a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual

ingredients

Short term May be absorbed through the skin and cause systemic effects. Use of this drug is habit

forming. Addiction may occur.

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include

lightheadedness, dizziness, sedation, sweating, nausea, vomiting, constriction of the pupil

(miosis), respiratory depression, respiratory arrest, circulatory failure, symptoms of

dependence/withdrawal.

Acute toxicity

Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation Based on av

Skin corrosion/irritation

Respiratory or skin sensitization STOT - single exposure

STOT - repeated exposure

Reproductive toxicity Germ cell mutagenicity Carcinogenicity

Aspiration hazard

Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Hydromorphone Hydrochloride
Rat Oral LD50 199 mg/kg

PZ03091

Page 8/12

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

Mouse Oral LD50 215-261 mg/kg Mouse Intravenous LD50 55 mg/kg

Citric acid

Mouse Oral LD50 5400 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Citric acid	= 3 g/kg (Rat)	> 2000 mg/kg (Rat)	-

Irritation / Sensitization: (Study Type, Species, Severity)

Citric acid

Eye Irritation Rabbit Severe Skin Irritation Rabbit Mild

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Hydromorphone Hydrochloride

Reproductive & Fertility Rat Oral 7 mg/kg/day NOAEL No evidence of impaired fertility or harm to the fetus

Embryo / Fetal Development Rabbit Oral 50 mg/kg/day NOAEL Not Teratogenic Embryo / Fetal Development Hamster Subcutaneous 14 mg/kg LOEL Teratogenic Embryo / Fetal Development Mouse Subcutaneous > 15 mg/kg/day LOEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Hydromorphone Hydrochloride

Bacterial Mutagenicity (Ames) Negative

Chromosome Aberration Human Lymphocytes Negative

In Vivo Micronucleus Mouse Negative

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or

OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the

environment should be avoided.

12.1. Toxicity

No information available

12.2. Persistence and degradability

Persistence and degradability No information available.

Page 9/12

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment		
Citric acid	Not PBT/vPvB		
Sodium Citrate	Not PBT/vPvB PBT assessment does not apply		

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:
UN proper shipping name:
Transport hazard class(es):
Packing group:
Environmental Hazard(s):
Not applicable
Not applicable
Not applicable

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

Page 10 / 12

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 231-791-2 AICS Present

Hydromorphone Hydrochloride

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
EINECS 200-762-6

Sodium Citrate

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
EINECS Not Listed
AICS Present
Standard for Uniform Scheduling of Medicines and Schedule 5

Poisons (SUSMP)

Citric acid

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS 201-069-1
AICS Present

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905 Not applicable

<u>Switzerland</u>

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018

Storage of Hazardous Material

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20

Major Accidents Ordinance SR 814.012

Not applicable
Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name Restricted substance per REACH Substance subject to authorization per

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

	Annex XVII	REACH Annex XIV
Citric acid	75	-
77-92-9		

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Biocidal Products Regulation (EU) No 528/2012 (BPR)

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)	
Citric acid	Product-type 2: Disinfectants and algaecides not intended	
77-92-9	for direct application to humans or animals Product-type 6	
	Preservatives for products during storage	

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing Chemicals Inventory

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H301 - Toxic if swallowed. H361d - Suspected of damaging the unborn child. H319 - Causes serious eye irritation. H335 - May cause respiratory irritation.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the

Company/Undertaking. Updated Section 3 - Composition / Information on Ingredients.

PZ03091

Page 11 / 12

Product Name Hydromorphone Hydrochloride Injection, USP CII

(Hospira Inc.)

Revision date 13-Jun-2025 Version 4

Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

Page 12/12

Updated Section 16 - Other Information.

Revision date 13-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.